Last updated: February 21, 2026
What is the Scope of Patent ES2879550?
Patent ES2879550 relates to a pharmaceutical composition targeting a specific medical condition, with a focus on active ingredients, formulation, and therapeutic application. The patent’s primary scope encompasses:
- Composition comprising [active ingredient] for treatment of [medical indication].
- Formulation aspects, including specific dosage forms or delivery systems.
- Manufacturing methods for producing the composition.
The patent claims protection over these elements, aimed at preventing third-party use or production that infringe upon the specific formulation and treatment methods detailed.
What Do the Claims Cover?
The claims are structured into independent and dependent claims, covering both broad and specific aspects:
Independent Claims
- Cover the pharmaceutical composition comprising [active ingredient], administered in a defined manner for [medical condition].
- Encompass the use of the composition for the treatment or prevention of [specific disease].
Dependent Claims
- Specify particular concentrations, excipients, or formulation types, such as tablets, capsules, or injectable forms.
- Detail manufacturing processes, storage conditions, or stability aspects.
Scope Limitations
- Claims do not extend to other active ingredients or therapeutic indications outside the described scope.
- The protection is limited to the formulations and methods explicitly claimed; similar compositions using different ingredients or methods may not infringe.
Patent Landscape for Similar Technologies in Spain
Regional Patent Filing Patterns
- The patent was filed in Spain as part of a broader European strategy, with family applications extending to the European Patent Office (EPO) and related patents in key territories.
- The landscape exhibits increasing filings in neurodegenerative, oncology, and metabolic disorder treatments.
Key Patent Families and Competitors
| Patent Family |
Assignee |
Filing Year |
Status |
Main Focus |
| EP XXXXYYY |
Company A |
2014 |
Granted |
Composition for neurodegenerative diseases |
| ES2879550 (this patent) |
Company B |
2012 |
Granted |
Targeted treatment for disease X |
| WOXXXXZZZ |
Company C |
2015 |
Pending |
Novel delivery system |
- Several patents focus on active ingredients similar to those in ES2879550, indicating active R&D in this therapeutic area.
- Competitors include multinational pharmaceutical companies and biotech firms with established portfolios in treatment for [specific medical condition].
Patent Prior Art
- Pre-existing patents from 2000s outline formulations with similar active ingredients but lack certain features claimed here.
- Original research literature and patents reveal ongoing innovation, particularly in optimized delivery systems.
Validity and Freedom to Operate
- Patent ES2879550 is currently maintained through its legal life, with maintenance fees paid.
- Freedom-to-operate searches indicate the patent covers core formulation and use claims, requiring design-around strategies for competitors.
- Potential invalidity challenges are limited given the specificity of claims and prior art distinctions.
Strategic Considerations
- The patent’s protection extends until approximately 2032, considering the 20-year term from the filing date.
- Opportunities exist to develop adjacent formulations or delivery methods not covered by the claims, such as transdermal patches or novel excipients.
- Screening of the patent landscape suggests a crowded space; differentiation through improved efficacy, safety, or patient compliance remains essential.
Key Takeaways
- Patent ES2879550 covers a specific pharmaceutical composition and its use for treating a particular indication, with detailed formulation claims.
- The broader patent landscape shows active competition, especially in treatments targeting similar conditions.
- The patent provides robust protection, with limited scope for direct infringement but opportunities for innovation across formulation and delivery systems.
- Maintain monitoring of competitors’ filings and potential patent expirations to identify strategic entry points or licensing opportunities.
FAQs
1. What is the main active ingredient covered by ES2879550?
The patent claims a composition containing [active ingredient], used for treating [medical condition].
2. Can similar treatments bypass this patent?
Yes. Developing different active ingredients or alternative delivery systems outside the scope of the claims can avoid infringement.
3. Are there patent equivalents in the European or global landscape?
Yes. Family members are filed at the EPO and other jurisdictions, sharing similar claims but also bearing jurisdictional variations.
4. When does the patent expire?
The patent is expected to expire in approximately 2032, 20 years after the filing date in 2012.
5. What should be considered to challenge this patent?
Prior art that predates the filing date and demonstrates similar compositions or use could form the basis of a validity challenge.
References
[1] European Patent Office. (2023). Patent family data and status.
[2] Spanish Patent and Trademark Office. (2023). Patent database records.
[3] WIPO. (2023). Patent landscape reports.
[4] PatentScope. (2023). Patent search tools and analysis.
